#Taiwan #Taipei #Formosa Pharmaceuticals #Clobetasol Propionate #Adalvo Limited

Formosa Pharmaceuticals Partners with Adalvo Limited for Innovative Eye Treatment

Taipei, May 28, 2025 - In a significant step towards advancing ophthalmic care, Formosa Pharmaceuticals, a leader in biotechnology based in Taiwan, has announced an exclusive licensing agreement with Adalvo Limited aimed at bringing their innovative clobetasol propionate ophthalmic suspension (0.05%) to the European and Brazilian markets. This unique formulation, known as APP13007, is designed to treat post-operative inflammation and pain following ocular surgeries.

Adalvo Limited is recognized as one of Europe’s top three B2B pharmaceutical companies, founded in 2018. It specializes in market access and has successfully launched nearly 1,100 drugs through its flexible and strategic business approaches. The partnership with Formosa allows Adalvo to market APP13007 under a system that includes upfront payments, sales milestones, and profit sharing, representing a promising financial structure to leverage its expertise and grow in both markets.

APP13007 is derived from Formosa's proprietary APNT® nanoparticle formulation platform, which facilitates optimized bioavailability and dosing regimens. The FDA's approval of this formulation in 2024 highlights its potential, allowing for dosing twice daily over a span of 14 days, offering patients effective and rapid relief from inflammation. A recent survey among 100 ophthalmic surgeons indicated a positive reception, with 80% of patients reporting pain resolution approximately four days post-surgery and an impressively low adverse event rate of less than 2%.

The market for ophthalmic treatments in Europe reached a substantial $16 billion in the year 2024, with cataract surgeries accounting for a large portion of the procedures performed. The demand for efficient post-operative treatments continues to rise, especially in major markets such as Germany and the UK. Projections suggest that this sector could escalate to a value of $38 billion by 2032, making now an opportune moment for both Formosa and Adalvo to expand their offerings.

Erick Co, President and CEO of Formosa Pharmaceuticals, expressed optimism about the collaboration, noting, "This partnership with Adalvo broadens our licensing initiatives in the European market significantly. Their established footprint and expertise make them an ideal partner for introducing APP13007 to clinicians and patients."

Anil Okay, Adalvo’s CEO, added, "Working with Formosa marks our commitment to enhancing patient access to innovative treatments. We are excited to be introducing APP13007 into new markets, reinforcing our goal to support differentiated solutions in key therapeutic areas."

About Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc. (6838.TW) is at the forefront of clinical-stage biotechnological advancements, focusing primarily on ophthalmology and oncology. Their technology, which focuses on nanoparticle formulations, enhances the delivery and efficacy of active pharmaceutical ingredients (APIs) across various administration routes. More information about Formosa can be found at formosapharma.com.

About Adalvo

Adalvo is an international pharmaceutical enterprise known for its strong B2B capabilities across more than 130 countries through partnerships with over 170 commercial entities. Their mission is to positively impact patient health worldwide through strategic collaborations and high-quality product offerings. More details can be discovered at adalvo.com.